Ginsenoside F2 | CAS:62025-49-4 | Manufacturer ChemFaces

Ginsenoside F2

ChemFaces products have been cited in many studies from excellent and top scientific journals

Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC

How to Order

Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com

Delivery time

Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal

Citing Use of our Products

More Impact Factor than five Cite...

* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.

According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.

Size /Price /Stock	10 mM * 1 mL in DMSO / $22.4 / In-stock
Other Packaging	*Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap

Featured Products

More...

Scutellarein

Catalog No: CFN98557
CAS No: 529-53-3
Price: $60/20mg

Xanthohumol

Catalog No: CFN98958
CAS No: 569-83-5; 6754-58-1
Price: $60/20mg

Luteolin

Catalog No: CFN98784
CAS No: 491-70-3
Price: $40/20mg

Sageone

Catalog No: CFN92166
CAS No: 142546-15-4
Price: $ / mg

Angelicide

Catalog No: CFN93012
CAS No: 92935-94-9
Price: $ / mg

Sophoricoside

Catalog No: CFN90148
CAS No: 152-95-4
Price: $40/20mg

Matrine

Catalog No: CFN98835
CAS No: 519-02-8
Price: $30/20mg

Scopolamine hydrobromide

Catalog No: CFN99709
CAS No: 114-49-8
Price: $30/20mg

Ginsenoside F2

Catalog No: CFN99755
CAS No: 62025-49-4
Price: $40/20mg

Acanthoside B

Catalog No: CFN97220
CAS No: 7374-79-0
Price: $268/20mg

Description:

Ginsenoside F2, an autophagic initiater, which has anti-cancer, and anti-obesity activities. Ginsenoside F2 inhibited the growth and invasion of cancer, and activated the intrinsic apoptotic pathway and mitochondrial dysfunction. Ginsenoside F2 suppresses hair cell apoptosis and premature entry to catagen more effectively than finasteride, it decreases the expression of TGF-β2 and SCAP proteins, the factors in the SCAP pathway could be targets for hair loss prevention drugs.

Targets:

PPAR | TGF-β/Smad | Wnt/β-catenin | Caspase | MMP(e.g.TIMP)

In vitro:

J Ginseng Res. 2012 Jan; 36(1): 86–92.

Anti-Cancer Effect of Ginsenoside F2 against Glioblastoma Multiforme in Xenograft Model in SD Rats[Pubmed: 23717108]

The glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. Despite combination treatments of radiation and chemotherapy, the survival periods are very short.
METHODS AND RESULTS:
Therefore, this study was conducted to assess the potential of Ginsenoside F2 (F2) to treat GBM. In in vitro experiments with glioblastoma cells U373MG, F2 showed the cytotoxic effect with IC50 of 50 μg/mL through apoptosis, confirmed by DNA condensation and fragmentation. The cell population of cell cycle sub-G1 as indicative of apoptosis was also increased. In xenograft model in SD rats, F2 at dosage of 35 mg/kg weight was intravenously injected every two days. This reduced the tumor growth in magnetic resonance imaging images. The immunohistochemistry revealed that the anticancer activity might be mediated through inhibition of proliferation judged by Ki67 and apoptosis induced by activation of caspase-3 and -8. And the lowered expression of CD31 showed the reduction in blood vessel densities. The expression of matrix metalloproteinase-9 for invasion of cancer was also inhibited. The cell populations with cancer stem cell markers of CD133 and nestin were reduced.
METHODS AND RESULTS:
The results of this study suggested that F2 could be a new potential chemotherapeutic drug for GBM treatment by inhibiting the growth and invasion of cancer.

In vivo:

Eur J Pharmacol. 2014 May 5;730:82-9.

The inductive effect of ginsenoside F2 on hair growth by altering the WNT signal pathway in telogen mouse skin.[Pubmed: 24613976]

This study was conducted to confirm the possibility of using minor ginseng saponin F2 by oral administration on hair anagen induction effects.
METHODS AND RESULTS:
The signaling pathway and anagen induction effect of Ginsenoside F2 were investigated and compared with finasteride on the effect of hair growth induction. The cell-based MTT assay results indicated that the proliferation rates of HHDPC and HaCaT treated with F2 significantly increased by 30% compared with the finasteride-treated group. A western blot study showed that the expression of β-catenin Lef-1 and DKK-1 increased by 140, 200% and decreased by 40% in the F2-treated group, respectively compared to that of finasteride-treated group. C57BL/6 mice were subjected to the same treatments. The hair growth promotion rates were compared with groups treated with finasteride, which was 20% higher in the F2-treated group. Tissue histological analysis results showed the number of hair follicles, thickness of the epidermis, and follicles of the anagen phase which increased in the F2-treated group, compared with the finasteride-treated groups. Moreover, the effect of F2 on hair growth was confirmed through the immunofluorescence (IF) methods indicating the expression aspect of Wnt signal pathway-related factors in the tissue of C57BL/6 mouse.
CONCLUSIONS:
Our results considered the expression increase in β-catenin, Lef-1 which was suggested as a major factor related to the development and growth of hair follicle and the decrease in DKK-1 when entering catagen by F2. As the data showed, F2 might be a potential new therapeutic source for anagen induction and hair growth through the Wnt signal pathway.

Ginsenoside F2 Description

Source:	The roots of Panax ginseng C. A. Mey.
Solvent:	DMSO, Pyridine, Methanol, Ethanol, etc.
Storage:	Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C). Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
After receiving:	The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.

Kinase Assay:

Cancer Lett. 2012 Aug 28;321(2):144-53.

Ginsenoside F2 induces apoptosis accompanied by protective autophagy in breast cancer stem cells.[Pubmed: 22326284]

Ginsenoside F2 (F2) was assessed for its antiproliferative activity against breast cancer stem cells (CSCs).
METHODS AND RESULTS:
F2 induced apoptosis in breast CSCs by activating the intrinsic apoptotic pathway and mitochondrial dysfunction. Concomitantly, F2 induced the formation of acidic vesicular organelles, recruitment of GFP-LC3-II to autophagosomes, and elevation of Atg-7 levels, suggesting that F2 initiates an autophagic progression in breast CSCs. Treatment with an inhibitor of autophagy enhanced F2-induced cell death.
CONCLUSIONS:
Our findings provide new insights into the anti-cancer activity of F2 and may contribute to the rational use and pharmacological study of F2.

Cell Research:

J Enzyme Inhib Med Chem. 2015 Feb;30(1):9-14.

Ginsenoside F2 possesses anti-obesity activity via binding with PPARγ and inhibiting adipocyte differentiation in the 3T3-L1 cell line.[Pubmed: 24666293]

Panax ginseng Meyer has been shown to be effective in mitigating various diseases. Protopanaxadiols (PPD) and protopanaxatriols (PPT), which are the main constituents of ginseng, have been shown to impact obesity.
METHODS AND RESULTS:
Therefore, we selected several important ginsenosides to perform our docking study and determine if they had binding affinity with the peroxisome proliferator activated receptor gamma (PPARγ), which is a major transcription factor in adipocytes. Among them, only a few ginsenosides demonstrated binding affinity with PPARγ. Other than Ginsenoside F2 rest of them were previously reported by the researchers in experimental study in case of obesity cell line 3T3-L1 adipocyte. In few recent studies, it was reported that F2 has protective effects on malignant brain tumors as well as anti-cancer activity in breast cancer. Therefore, we felt it was important to focus on F2 when considering obesity. Our study focused on this ginsenoside and analyzed its impact on 3T3-L1 adipocytes. Following the molecular interaction studies, further experimental studies were carried out and demonstrated that Ginsenoside F2 when treated with different doses reduces the level of lipid accumulated by the 3T3-L1 cell line during adipogenesis. Reverse transcriptase polymerase chain reaction (RT-PCR) and quantitative real-time PCR results showed reduction in PPARγ and perilipin gene expression levels compared to that of differentiated adipocytes without any treatment.
CONCLUSIONS:
So considering the binding with a major adipocyte transcription factor and the performed experiments, we suggest that Ginsenoside F2 may reduce obesity via the inhibition of adipogenesis in the 3T3-L1 cell line.

Product Name	Ginsenoside F2
Price:	$40 / 20mg
CAS No.:	62025-49-4
Catalog No.:	CFN99755
Molecular Formula:	C₄₂H₇₂O₁₃
Molecular Weight:	785.01 g/mol
Purity:	>=98%
Type of Compound:	Triterpenoids
Physical Desc.:	Powder
Source:	The roots of Panax ginseng C. A. Mey.
Solvent:	DMSO, Pyridine, Methanol, Ethanol, etc.
Download:	COA MSDS SDF Manual
Similar structural:	Comparison (Web) (SDF)
Guestbook:

Size /Price /Stock	10 mM * 100 uL in DMSO / Inquiry / In-stock 10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries	Anticancer Compound Library Anti-adipogenic Compound Library Triterpenoids Compound Library Wnt/β-catenin Inhibitor Library TGF-β/Smad Inhibitor Library PPAR Inhibitor Library MMP(e.g.TIMP) Inhibitor Library Caspase Inhibitor Library

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	1.2739 mL	6.3693 mL	12.7387 mL	25.4774 mL	31.8467 mL
5 mM	0.2548 mL	1.2739 mL	2.5477 mL	5.0955 mL	6.3693 mL
10 mM	0.1274 mL	0.6369 mL	1.2739 mL	2.5477 mL	3.1847 mL
50 mM	0.0255 mL	0.1274 mL	0.2548 mL	0.5095 mL	0.6369 mL
100 mM	0.0127 mL	0.0637 mL	0.1274 mL	0.2548 mL	0.3185 mL

CFN99967	Ginsenoside Rg1	22427-39-0	801.01	C₄₂H₇₂O₁₄
CFN99999	Notoginsenoside R1	80418-24-2	933.13	C₄₇H₈₀O₁₈
CFN99974	Ginsenoside Re	52286-59-6	947.15	C₄₈H₈₂O₁₈
CFN99975	Ginsenoside Rd	52705-93-8	947.2	C₄₈H₈₂O₁₈
CFN93372	Gypenoside XLVI	94705-70-1	963.2	C₄₈H₈₂O₁₉
CFN90757	Ginsenoside F4	181225-33-2	767.0	C₄₂H₇₀O₁₂
CFN95248	Quasipanaxatriol	171903-78-9	458.7	C₃₀H₅₀O₃
CFN95232	Ginsenoside MC	175484-06-7	755.0	C₄₁H₇₀O₁₂
CFN96182	Gynosaponin I	1207861-69-5	769.0	C₄₂H₇₂O₁₂
CFN95331	Gynosaponin TN2	77658-95-8	785.0	C₄₂H₇₂O₁₃